The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

State Medicaid programs already are allowed to offer GLP-1 drugs for weight loss, but only 13 state programs currently do so.

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

Cigna has sold its Medicare businesses and slashed the number of people it covers in its ACA plans by more than half.

Full year 2025 pretax adjusted earnings outlooks for Evernorth and Cigna Healthcare remain at "at least $7.2 billion" and "at least $4.125 billion" respectively. The company expects the full year ...

The report, compiled for The New York Times by health analytics company Komodo Health, shows that denial rates rose from 18.3 ...

UnitedHealth Group's pharmacy benefits manager, OptumRx Inc., was hit with an Employee Retirement Income Security Act of 1974 lawsuit for allegedly improperly approving more than $4.3 million for ...

Over half of large US employers plan to cut health benefits in 2026 as rising costs of weight-loss drugs like Wegovy drive up ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

Weight-loss drug costs are top concern for 77% of employers Over half of large employers plan to increase cost-sharing Employers seek alternatives to pharmacy benefit managers More than half of large ...